title: [Efficacy and tolerability of the combination of oxaliplatin, ifosfamide, and epirubicin in treatment of recurrent or platinum-resistant ovarian epithelial cancer patients].
abstract: OBJECTIVE
  To evaluate the efficacy and tolerability of the combination of oxaliplatin, ifosfamide and epirubicin (IAP) in treatment of recurrent or platinum-resistant ovarian cancer patients.
  
  
  METHODS
  A total of 25 patients received the combined chemotherapy of ifosfamide (3 - 4 g/m(2)), epirubicin (50 - 60 mg/m(2)) and oxaliplatin (130 mg/m(2)). The cycles were repeated every 21 days. The efficacy and toxicity were evaluated in 21 patients who received more than 2 cycles of IAP chemotherapy.
  
  
  RESULTS
  The overall response rate was 71%, with a complete response in 10 (48%), partial response in 5 (24%), stable disease in one (5%), and disease progression in 5 (24%). The median progression-free and overall survival time were 11 (1 to 33) months and 31 (1 to 71) months. While overall response rate was 60% in 10 patients with primary platinum resistant, and 88% in 8 patients with secondary platinum-resistant. Grade III - IV myelosuppression rate was 30%. The most common non-hematologic toxicity was perineurotoxicity (38%).
  
  
  CONCLUSIONS
  The combination of oxaliplatin, ifosfamide and epirubicin appears to be effective for recurrent or platinum-resistant ovarian cancer patients as salvage chemotherapy and the toxicity is also tolerable. However, it needs to be evaluated by multiple clinical trials.
authors.affiliation: Department of Gynecology, Peking University People's Hospital, Beijing 100044, China.
authors.forename: Xiao-Ping
authors.initials: XP
authors.lastname: Li
authors.forename: Heng
authors.initials: H
authors.lastname: Cui
authors.forename: Jing-Wei
authors.initials: JW
authors.lastname: Zhou
authors.forename: Li-Hui
authors.initials: LH
authors.lastname: Wei
authors.forename: Jian-Liu
authors.initials: JL
authors.lastname: Wang
authors.forename: Yan
authors.initials: Y
authors.lastname: Zhao
authors.forename: Yue
authors.initials: Y
authors.lastname: Wang
authors.forename: Shi-Jun
authors.initials: SJ
authors.lastname: Wang
authors.forename: Hong-Lan
authors.initials: HL
authors.lastname: Zhu
authors.forename: Li
authors.initials: L
authors.lastname: Dong
authors.forename: Hong
authors.initials: H
authors.lastname: Zhang
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002945:Cisplatin / Q000009:adverse effects / Q000627:therapeutic use; D004317:Doxorubicin / Q000009:adverse effects / Q000627:therapeutic use; D004334:Drug Administration Schedule; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D007069:Ifosfamide / Q000009:adverse effects / Q000627:therapeutic use; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D009503:Neutropenia / Q000209:etiology; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D011379:Prognosis; D016896:Treatment Outcome
chemical_list: D004317:Doxorubicin; D002945:Cisplatin; D007069:Ifosfamide